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Background: Villoglandular adenocarcinoma (VGA) of the uterine cervix is a relatively rare subtype of
endocervical adenocarcinomas that often occurs in early reproductive women.
Methods: Clinical cases were retrospectively collected from the cancer registry systems at Mackay
Memorial Hospital (Taipei, Taiwan). Clinical histories on the subjects were extracted directly from chart
review of records of clinic visits.
Results: The mean age of 12 subjects was 42 years, with 10 and 2 subjects clinically staged as IB1 (10 of
12) and IA2 (2 of 12), respectively, for the period between January 1, 1996, and December 31, 2007. Eleven
subjects had classical Type III radical hysterectomy with or without bilateral salpingo-oophorectomy plus
bilateral pelvic lymphadenectomy, and one received pelvic and para-aortic lymphadenectomy plus
postoperative adjuvant treatment of weekly cisplatin concurrent with radiotherapy. Only one subject had
conﬁrmed pelvic lymph nodes metastases. Nine subjects had pure histologic type and others had mixed
histologic type of VGA. Only one subject had a recurrence but was still alive. Most subjects were long-
term survivors (greater than 5 years) (10 of 12).
Conclusion: In conclusion, this study conﬁrms the young age of subjects with VGA and reemphasizes the
difﬁculties in the diagnosis of VGA. Because the current management strategy renders good tumor
control in young subjects with early-stage VGA, we would suggest that similar treatment should be
considered for elder subjects with this rare category of cervical malignancy. Our experience shows that
the primary management of subjects with early-stage VGA (International Federation of Gynecology and
Obstetrics Stages IA2 to IIA1) is classical Type III radical hysterectomy plus salpingo-oophorectomy with
bilateral pelvic lymphadenectomy at MMH. We hope our 12-case experience may contribute to the
clinical decision making for subjects with this disease.
Copyright  2011, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Villoglandular adenocarcinoma (VGA) of the uterine cervix was
ﬁrst reported not too long ago by Young and Scully1 in 1989. It
became a recognized disease entity in World Health Organizationpartment of Obstetrics and
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1994. VGA represents a rare subtype of endocervical adenocarci-
nomas among mucinous adenocarcinomas that accounts for
approximately 4% of all cervical adenocarcinomas3. The character-
istic tumor histology of VGA is its extremely villous growth, well-
deﬁned papillary architecture, and minimal atypia on cytological
features when compared with the common types of cervical
adenocarcinomas. Recognition of this tumor as a distinct disease
entity is of high clinical importance because VGA often occurs in
early reproductive women (with a mean age of 33 years1) than
other malignant tumors of uterine cervix. Clinically, the relatively
indolent behavior of VGA is generally regarded as having an
“exceptional better prognosis” and a very good treatment outcomecy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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amore conservativemanagement, especially in subjects who desire
to preserve future fertility without a considerable adverse effect on
cure rates. A different therapy is, therefore, selected for individual
subjects on the basis of clinical experiences for this rare malig-
nancy. We retrospectively analyzed the clinical cases of the VGA of
the uterine cervix to learn more about treatment effectiveness in
terms of survivorship and to identify possible prognostic factors
responsible for the overall survival in women with this rare
malignancy. The data that resulted from 12 years of clinical studies
on VGA subjects at Mackay Memorial Hospital (MMH) (Taipei,
Taiwan) were revisited and reorganized based on the histologic
features proposed by WHO2 in 1994. After careful review, we
present 12-case experience about diagnosis, treatment, and prog-
nosis of this carcinoma.
2. Materials and Methods
Individual-subject data were retrospectively collected from the
cancer registry systems at MMH. The registry collects basic demo-
graphic data on subjects, including age at diagnosis, date of diag-
nosis, and clinical International Federation of Gynecology and
Obstetrics (FIGO) stage of disease at the timeof clinical presentation.
The review of the cancer registry system was limited to the period
between January 1, 1996, and December 31, 2007. All VGA cases
identiﬁed as “villoglandular adenocarcinoma,” “well-differentiated/
differentiated villoglandular adenocarcinoma,” “adenocarcinoma,”
“mucinous papillary adenocarcinoma,” or “well-differentiated/
differentiated adenocarcinoma” in the original pathology report
were initially retrieved from the cancer registry system and exam-
ined by a gynecologic pathologist (Wang T.-Y., MD). Subject selec-
tion was performed by the same pathologist as a means of
maintaining internal-data consistency. The criteria used for diag-
nosing VGA tumors were based on the morphological characteris-
tics as deﬁned by WHO2. During the study period, a total of 2,536
subjects were identiﬁed with cervical cancer. On reinspection,
subjects with squamous cell carcinoma, other types of adenocarci-
nomas, or those who had only foci of villoglandular patterns were
initially excluded from the study. Three of the four cases of adeno-
carcinoma were reassigned to the category of pure VGA and one to
VGA in situ combined with focal microinvasive squamous cell
carcinoma. Three of the four pure VGA cases were reassigned to the
categories of endocervical adenocarcinoma and one to “mixed
adenocarcinoma and VGA.” One well-differentiated VGA case was
reassigned to adenosquamous carcinoma. A total of 14 subjects
consistent with VGAwere at ﬁrst retrieved from the cancer registry
systems. One subject was lost to follow-up, and a subject chart wasTable 1
Clinical proﬁles and related statistics of subjects with villoglandular adenocarcinoma (n
Patient no. FIGO stage Age (y/o) Pathologic diagnosis
1 IA2 32 VGA in situ and focal microinvasive SC
2 IA2 46 Pure VGA
3 IB1 48 Pure VGA
4 IB1 32 Pure VGA
5 IB1 33 Pure VGA
6 IB1 39 Pure VGA
7 IB1 39 Pure VGA
8 IB1 42 VGA and small foci of SCC in situ
9 IB1 47 Pure VGA
10 IB1 49 Adeno Ca and VGA
11 IB1 50 Pure VGA
12 IB1 52 Pure VGA
Adeno Ca¼ adenocarcinoma; BPLND¼ bilateral pelvic lymphadenectomy; BSO¼ b
mo¼months; FIGO¼ International Federation of Gynecology and Obstetrics; PALND
SCC¼ squamous cell carcinoma; VGA¼ villoglandular adenocarcinoma; y/o¼ years old.incomplete. Only 12 subjects (12 of 2,536, 0.47%) were, thus, iden-
tiﬁed and selected for the study.
Clinical histories on the subjects were extracted directly from
chart review of records of clinic visits. Relevant clinical data
included any test results related to the subjects (e.g., age at diag-
nosis; date of diagnosis; FIGO stage at diagnosis; presenting
symptoms; treatment regimes, including surgery, radiation,
chemotherapy, or any combination of them; cervical tumor size;
locations and microscopic depths of cervical stromal invasion;
serum tumor markers [squamous cell carcinoma (SCC), carci-
noembryonic antigen (CEA), or cancer antigen 125 (CA-125)], the
presence of other histologic types of cervical malignancy; and
nature of follow-up). The overall survival was deﬁned as the time
from initial diagnosis to the time of death or last follow-up. All
survived subjects were followed up until September 30, 2009. The
study was approved by the Institutional Review Boards and Ethics
Committees of the hospital.
3. Results
The clinical proﬁles and related statistics of all subjects are given
in Table 1. All subjects were adult women with a mean age of 42.4
years (median, 44 years; range, 32e52 years) at initial diagnosis.
Most of them were multiparous, nonsmokers, and premenopausal.
FIGO Stage IB1 was the most common clinical stage for most
subjects (10 of 12). Most of the subjects exhibited pure-type
histologic pattern (9 of 12), and only three subjects exhibited
mixed-type histologic pattern (3 of 12). The tumors had a mean
diameter of 3.43 cm (median, 3 cm; range, 3e4 cm).
Eleven subjects were treated with classical Type III radical
hysterectomy (RH) (11 of 12), and none of these subjects received
postoperative adjuvant treatment (0 of 11). RH surgeries referred to
RH surgery with either bilateral salpingo-oophorectomy (BSO) plus
bilateral pelvic lymphadenectomy (BPLND) (RHþ BSOþ BPLND) (8
of 11); RH plus BPLND (2 of 11); or RH plus BSO, BPLND, and para-
aortic lymphadenectomy (PALND) (RHþ BSOþ BPLNDþ PALND) (1
of 11). Only one subject received non-hysterectomy surgery
(BLPNDþ PALND), followed by postoperative adjuvant treatment of
weekly cisplatin concurrent with radiotherapy (CCRT).
The data on pelvic lymph node (PLN) metastases were available
for all subjects. Only one subject was conﬁrmed positive for PLN
metastasis, and shewas also conﬁrmedpositive for PALNmetastasis.
Tumor gradewas available for all except two subjects with pure-
type histologic pattern (10 of 12). Subjects with pure-type histo-
logic pattern had 71% Grade 1 (ﬁve of seven) and 29% Grade 2
tumor cells (two of seven), whereas all subjects with mixed-type
histologic pattern had Grade 1 tumor cells (three of three).¼ 12)
Primary treatment Adjuvant therapy Follow-up (mo)
C RHþ BSOþ BPLNDþ PALND No 151
RHþ BSOþ BPLND No 99
RHþ BSOþ BPLND No 153
RHþ BPLND No 117
RHþ BSOþ BPLND No 149
RHþ BSOþ BPLND No 124
RHþ BSOþ BPLND No 109
RHþ BPLND No 138
RHþ BSOþ BPLND No 162
RHþ BSOþ BPLND No 50
BPLNDþ PALND CCRT 110
RHþ BSOþ BPLND No 34
ilateral salpingo-oophorectomy; CCRT¼ concurrent chemo-radiation therapy;
¼ para-aortic lymphadenectomy; RH¼ classical Type III radical hysterectomy;
VGA of the Uterine Cervix 51Eleven subjects were still alive with no evidence of the disease
(11 of 12). Only one subject had a recurrence (1 of 12) but was still
alive. Most subjects were long-term survivors (greater than 5 years)
(10 of 12). The mean survival time for all subjects was 116.3 months
(median, 121 months; range, 34e162 months).
4. Discussion
Although early-stage VGA of uterine cervix is extremely rare,
subjects with these diseases are often associated with very good
treatment outcome and low recurrences. Many clinicians have
attempted to identify the prognostic factors for VGA, but limited
clinical cases have rendered all attempts futile. A search of the
Medline and Embase electronic databases reveals 118 cases1,4e32 of
VGA reported in the English literature worldwide between 1989
and 2009. Approximately 60% of the retrievable studies are single-
case reports. Only four studies have presented a series of more than
10 clinical cases, including studies by Young and Scully (1989)1;
Jones et al. (1993)4; Khunamornpong et al. (2001)22; and Utsugi
et al. (2004)31. This is the ﬁfth study that presents our experience on
a small series of 12 clinical cases.
Unlike cervical adenocarcinoma that occurs in subjects whose
average age is in the late 40s and 50s, VGA is a well-differentiated
form of cervical adenocarcinomas, which occurs predominantly in
young women. In the ﬁrst description of 13 subjects with VGA
described by Young and Scully1, the mean age was 33 years. Jones
et al.4 reported a mean age of 37 years in their study of 24 cases;
Khunamornpong et al.22 described a series of 15 cases with a mean
age of 39 years; and Utsugi et al.31 presented 13 cases with a mean
age of 45 years. In our series, the mean age was 42 years. Because
RH often gives rise to infertility, the favorable prognosis and the less
aggressive behavior often associated with VGA leads some doctors
to conduct a more conservative surgical procedure in selected cases
of young women with operable diseases, such as conization1,4,9,
especially for those who wish to remain fertile. However, this
conjecture still evokes controversy and receives much dispute.
The conventional management of subjects with early-stage
invasive adenocarcinomas (Stage IA1 to IIA) is RH with pelvic lym-
phadenectomy or radiotherapy. Among the 118 reported cases, only
15 subjects underwent conization, 98 had hysterectomies, and 5
received other modalities, such as CCRT. Ninety-eight subjects were
managed either by RH (79 of 98), extended hysterectomy (2 of 98),
or simple hysterectomy (13 of 98). Surgical procedures of hyster-
ectomywere notmentioned in four subjects. BPLNDwas conducted
in 59 subjects, and 9 of 59 also underwent PALND. In our series, 11
subjects had RH plus BPLND, and one also underwent PALND. Only
Patient 11 had BLPND plus PALND and postoperative CCRT.
The diagnosis of VGA has always been challenging for patholo-
gists. Because the reported rate of pretreatment misdiagnosis is
often high, the marked distinction in the prognosis between a VGA
and a common cervical adenocarcinoma has highlighted the
importance of a proper clinical diagnosis of VGA. Only three out of
15 VGA cases were in agreement among the reviewers in a study by
Alfsen et al.33 examining the reproducibility of histological classi-
ﬁcation of nonesquamous cell carcinomas of the uterine cervix. In
our series, after reexamination by a pathologist, three cases of pure
VGA and one case of VGA in situ combined with focal microinvasive
squamous cell carcinoma were initially misdiagnosed as adenocar-
cinoma. On the other hand, three cases of endocervical adenocar-
cinoma and one case of adenosquamous carcinoma were originally
diagnosed as pure VGA cases.
Most studies described VGA as having a good long-term prog-
nosis and being free of recurrences4,13,17. However, the four recurred
cases reported by MacDonald et al.26, Korach et al.30, and Kaku
et al.10 reveal an deﬁnite discrepancy between the “excellent betterprognosis” of VGA described in the original series of 13 subjects by
Young and Scully (1989)1 and subsequent reports by other
authors13,18,20. MacDonald et al.26 described two recurred VGA
subjects: one 32-year-old subject, staged IIB, died from recurrence 2
months later after CCRT. The other 31-year-old subject, staged IB2,
initially treated by RH plus BPLND, developed vaginal recurrence 6
months postoperatively. Although abnormality disappeared from
the vaginal vault after completion of CCRT, metastatic adenocarci-
noma with a VGA pattern was discovered as a nodule at the drain
site from the original RH. After further nodule excision and
completed postoperative radiotherapy, this subject developed
a further pelvic recurrence and was then receiving palliative treat-
ment. Korach et al.30 reported a 34-year-old subject, staged IB1 and
having undergone RH plus BSO with BPLND, who died of tumor
recurrence in the pelvic sidewall and presacral lesions 2 years after
treatment. Kaku et al.10 reported a 54-year-old woman, clinically
staged as FIGO Stage IIB and having undergone RH plus BPLND
followed by radiation therapy, who developed vaginal recurrence
and died of the disease at 46 months after initial treatment. In our
series, Patient 3 was the only subject with recurrence, who was 48
years old and had FIGO Stage IB1 disease. This subject was
conﬁrmed negative for both PLN and PALNmetastases and was still
alive at last follow-up. The case reported in this studywould ﬁt with
the aforementioned four cases butwould probably not be consistent
with the original deﬁnition by Young and Scully1.
The presence of lymph node metastases (pelvic or para-aortic) is
recognized as one of the most signiﬁcant prognostic factors that
determines recurrences and survival of subjects in cervical adeno-
carcinomas. Only three deaths out of eight reported cases of lymph
nodemetastaseshavebeenreported in threesingle-case reports7,26,32
and three series10,22,31 among 118VGA cases publishedworldwide. In
our series, lymph node metastasis was observed only in Patient 8,
who was conﬁrmed positive for both PLN and PALN metastases.
Our study suffers from insufﬁcient numbers of subjects, which is
a common limitation for a rare disease, such as VGA. It would be
necessary to enroll very large numbers of subjects to address the
various aspects of treatment methods (CT and surgery, alone or in
combination) and their clinical roles in VGA.
In conclusion, this study conﬁrms the young age of subjects with
VGA and reemphasizes the difﬁculties in the diagnosis of VGA.
Although we have known VGA for 21 years since its ﬁrst report, the
lack of deﬁned clinical and histologic features of this tumor
combined with its rarity contributes further to its misdiagnosis. In
view of the fact that a subject in our series had recurrence and
another subject was conﬁrmed positive for both PLN and PALN
metastases, we do not agree with the “excellent prognosis” that is
usually related to this disease. Because the current management
strategy renders good tumor control in young subjects with early-
stage VGA, we would suggest that similar treatment should be
considered for elder subjects with this rare category of cervical
malignancy. We recommend that the management of both young
and elder subjects with VGA should follow the conventional
treatments for cervical adenocarcinomas until more evidences are
available to us. Our experience shows that the primary manage-
ment of subjects with early-stage VGA (FIGO Stages IA2 to IIA1) is
classical Type III RH plus BSOwith BPLND atMMH.We hope our 12-
case experience may contribute to the clinical decision making for
subjects with this disease.
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